Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges
First International Summit on Interventional PharmacoeconomicsAdvertisement
Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.
